Cargando…

Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms

HIGHLIGHTS: What are the main findings of the study? The most-used pain medication during COVID-19 is acetaminophen. The most common analgesics used in post-COVID-19 are acetaminophen, ibuprofen or other NSAID, while older subjects prefer acetaminophen. The frequency of pain medication is often seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Galluzzo, Vincenzo, Zazzara, Maria Beatrice, Ciciarello, Francesca, Tosato, Matteo, Bizzarro, Alessandra, Paglionico, Annamaria, Varriano, Valentina, Gremese, Elisa, Calvani, Riccardo, Landi, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142362/
https://www.ncbi.nlm.nih.gov/pubmed/37109328
http://dx.doi.org/10.3390/jcm12082992
_version_ 1785033594861780992
author Galluzzo, Vincenzo
Zazzara, Maria Beatrice
Ciciarello, Francesca
Tosato, Matteo
Bizzarro, Alessandra
Paglionico, Annamaria
Varriano, Valentina
Gremese, Elisa
Calvani, Riccardo
Landi, Francesco
author_facet Galluzzo, Vincenzo
Zazzara, Maria Beatrice
Ciciarello, Francesca
Tosato, Matteo
Bizzarro, Alessandra
Paglionico, Annamaria
Varriano, Valentina
Gremese, Elisa
Calvani, Riccardo
Landi, Francesco
author_sort Galluzzo, Vincenzo
collection PubMed
description HIGHLIGHTS: What are the main findings of the study? The most-used pain medication during COVID-19 is acetaminophen. The most common analgesics used in post-COVID-19 are acetaminophen, ibuprofen or other NSAID, while older subjects prefer acetaminophen. The frequency of pain medication is often several times a week. What is the implication of the main findings? The need to continue analgesic therapy after COVID-19 is associated with persistent arthralgia and myalgia. Most patients report an improvement in pain perception after taking analgesic therapy. ABSTRACT: Background—Analgesics could be used to manage painful symptoms during and after COVID-19. Materials and methods—Persistence of painful symptoms was assessed during and after COVID-19 in a sample of patients admitted to a post-acute COVID-19 outpatient service in Rome, Italy. Data on type and frequency of use of first-line analgesics were collected. Pain severity was evaluated with a numeric rating scale (NRS) from 0 to 10. Results—Mean age of 696 participants was 57.1 ± 20.3 years and 61.7% were women. During COVID-19, the most prevalent symptoms were fever, fatigue, arthralgia, myalgia and headache. Acetaminophen was used by 40% of the sample. Only 6.7% needed to continue analgesic therapy after COVID-19. Frequent causes of analgesics consumption were persistent arthralgia and myalgia. The most common analgesics used amongst those who continued taking analgesics in the post-acute phase of COVID-19 were the following: acetaminophen (31%), ibuprofen (31%) and other non-steroidal anti-inflammatory drug (NSAID) (29.5%); in older subjects the most common analgesic used was acetaminophen (54%). Most of the subjects in this group said there was an improvement in pain perception after taking analgesic therapy (84%). Conclusions—Use of analgesics in the post-acute COVID-19 is common in subjects with persistent arthralgia and myalgia, and common analgesics were acetaminophen and ibuprofen. Further research on the safety and efficacy of those medications in COVID-19 is warranted.
format Online
Article
Text
id pubmed-10142362
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101423622023-04-29 Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms Galluzzo, Vincenzo Zazzara, Maria Beatrice Ciciarello, Francesca Tosato, Matteo Bizzarro, Alessandra Paglionico, Annamaria Varriano, Valentina Gremese, Elisa Calvani, Riccardo Landi, Francesco J Clin Med Article HIGHLIGHTS: What are the main findings of the study? The most-used pain medication during COVID-19 is acetaminophen. The most common analgesics used in post-COVID-19 are acetaminophen, ibuprofen or other NSAID, while older subjects prefer acetaminophen. The frequency of pain medication is often several times a week. What is the implication of the main findings? The need to continue analgesic therapy after COVID-19 is associated with persistent arthralgia and myalgia. Most patients report an improvement in pain perception after taking analgesic therapy. ABSTRACT: Background—Analgesics could be used to manage painful symptoms during and after COVID-19. Materials and methods—Persistence of painful symptoms was assessed during and after COVID-19 in a sample of patients admitted to a post-acute COVID-19 outpatient service in Rome, Italy. Data on type and frequency of use of first-line analgesics were collected. Pain severity was evaluated with a numeric rating scale (NRS) from 0 to 10. Results—Mean age of 696 participants was 57.1 ± 20.3 years and 61.7% were women. During COVID-19, the most prevalent symptoms were fever, fatigue, arthralgia, myalgia and headache. Acetaminophen was used by 40% of the sample. Only 6.7% needed to continue analgesic therapy after COVID-19. Frequent causes of analgesics consumption were persistent arthralgia and myalgia. The most common analgesics used amongst those who continued taking analgesics in the post-acute phase of COVID-19 were the following: acetaminophen (31%), ibuprofen (31%) and other non-steroidal anti-inflammatory drug (NSAID) (29.5%); in older subjects the most common analgesic used was acetaminophen (54%). Most of the subjects in this group said there was an improvement in pain perception after taking analgesic therapy (84%). Conclusions—Use of analgesics in the post-acute COVID-19 is common in subjects with persistent arthralgia and myalgia, and common analgesics were acetaminophen and ibuprofen. Further research on the safety and efficacy of those medications in COVID-19 is warranted. MDPI 2023-04-20 /pmc/articles/PMC10142362/ /pubmed/37109328 http://dx.doi.org/10.3390/jcm12082992 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Galluzzo, Vincenzo
Zazzara, Maria Beatrice
Ciciarello, Francesca
Tosato, Matteo
Bizzarro, Alessandra
Paglionico, Annamaria
Varriano, Valentina
Gremese, Elisa
Calvani, Riccardo
Landi, Francesco
Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms
title Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms
title_full Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms
title_fullStr Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms
title_full_unstemmed Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms
title_short Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms
title_sort use of first-line oral analgesics during and after covid-19: results from a survey on a sample of italian 696 covid-19 survivors with post-acute symptoms
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142362/
https://www.ncbi.nlm.nih.gov/pubmed/37109328
http://dx.doi.org/10.3390/jcm12082992
work_keys_str_mv AT galluzzovincenzo useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms
AT zazzaramariabeatrice useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms
AT ciciarellofrancesca useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms
AT tosatomatteo useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms
AT bizzarroalessandra useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms
AT paglionicoannamaria useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms
AT varrianovalentina useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms
AT gremeseelisa useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms
AT calvaniriccardo useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms
AT landifrancesco useoffirstlineoralanalgesicsduringandaftercovid19resultsfromasurveyonasampleofitalian696covid19survivorswithpostacutesymptoms